Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter

NCT ID: NCT01448265

Last Updated: 2013-07-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-09-30
• Study Completion Date: 2013-07-31

Brief Summary

Background: Atrial fibrillation (AF) is the most frequent sustained cardiac arrhythmia, impairs quality of life and increases stroke risk and mortality. Recent clinical experience with the Arctic Front™ cryoballoon ablation catheter system (Medtronic) suggests that it can be used to isolate the pulmonary veins (PVs) safely and effectively in patients with AF, thereby eliminating the recurrence of AF.

Hypothesis: Our hypotheses are (1) that visualization of real-time pulmonary vein conduction during cryoballoon ablation of atrial fibrillation using a novel spiral circumferential mapping catheter (Achieve™) is feasible and safe, and (2) that procedure and fluoroscopy times decrease with experience.

Objective: The purpose of this study is to assess safety, feasibility, and a learning curve associated with cryoballoon catheter ablation using a novel circular mapping catheter (Achieve™, Medtronic) inserted through the lumen of the cryoballoon in patients with symptomatic paroxysmal atrial fibrillation.

The primary goal is to evaluate successful pulmonary vein isolation using the Achieve™ mapping catheter. The reduction of procedure and fluoroscopy times during the first 40 patients treated with this approach will be analyzed to evaluate a potential learning curve upon introduction of the technique.

Detailed Description

A total of 40 patients scheduled for a first ablation of paroxysmal AF will be included. All study subjects will undergo cryoablation using the 28 mm Arctic Front™ Cryoablation Catheter. A double transseptal approach will be followed in all study patients, allowing for use of regular guide wire and circular mapping catheter, respectively, if required.

Use of the 20 mm Achieve™ circular mapping catheter is preferred. The 15 mm AchieveTM catheter may be used at the physician's discretion. If stable balloon positions cannot be obtained, the Achieve™ catheter will be replaced by a regular guide wire and pulmonary vein isolation will be assessed by a circular mapping catheter (Lasso™; Biosense Webster) introduced through a second transseptal puncture. Cryoablations will be applied for 5 minutes each. Premature terminations will be allowed at the physician's discretion but should be avoided to allow for detection of late pulmonary vein isolation during cryoenergy application. Cryoballoon catheter manipulations (e.g., pull down maneuver) may be performed during energy application. During ablation of septal pulmonary veins, electrical phrenic nerve stimulation will be performed to exclude phrenic nerve palsy. If additional single point ablations are required to achieve electrical isolation of pulmonary veins, a linear cryocatheter (Freezor™ Max; Medtronic) will be used.

Conditions

Atrial Fibrillation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Paroxysmal atrial fibrillation.

Group Type: EXPERIMENTAL

Cryoballoon ablation.

Intervention Type: PROCEDURE

Cryoballoon ablation using a novel circular mapping catheter.

Interventions

Cryoballoon ablation.

Cryoballoon ablation using a novel circular mapping catheter.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Documented paroxysmal atrial fibrillation
• ≥18 and ≤75 years of age
• Failure of one or more antiarrhythmic drugs
• Referral for a pulmonary vein isolation catheter ablation procedure to treat atrial fibrillation

Exclusion Criteria

• Previous ablation of atrial fibrillation
• Documented left atrial thrombus
• Irregular pulmonary vein anatomy according to transesophageal echocardiography
• Atrial fibrillation secondary to reversible cause
• Amiodarone therapy in the previous 6 months
• Cardiac surgery within the prior 6 months
• Myocardial infarction within the previous 2 months
• Ejection fraction < 40%
• NYHA class III or IV
• Moderate to severe valvular heart disease
• Previous valve replacement
• Pacemaker or implantable cardioverter defibrillator placement in the prior 3 months
• History of stroke or TIA within the previous 12 months
• Left atrial size ≥ 50 mm
• Contraindication for anticoagulation medication
• Life expectancy of less than 12 months
• Pregnancy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medtronic

INDUSTRY

Sponsor Role: collaborator

Heidelberg University

OTHER

Sponsor Role: lead

Responsible Party

Dierk Thomas, M.D.

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Dierk Thomas, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Cardiology, University of Heidelberg

Locations

Department of Cardiology, University of Heidelberg

Heidelberg, , Germany

Countries

Germany

Other Identifiers

CRYO-MAP

Identifier Type: -

Identifier Source: org_study_id